- Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for Caswell-Jin, J., Shafaee, M., Liu, M., Xiao, L., John, E. M., Bondy, M., Kurian, A. W. Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Surveys were sent 2months post-surgery, (70% response rate, n=5080). Imputing HLA genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient. Impact of cancer worry did not substantively differ by test type, test result outcomes, or clinical or treatment factors. George Kurian was appointed CEO of $5.5 billion storage company NetApp about a year ago after a fast, meteoric rise at the company. We further identified one of the five credible causal variants at signal 2, a 1.4 kb deletion (esv3594306), as the likely causal variant; the deletion allele of this variant was associated with an average additional increase in IGFBP5 expression of 1.3-fold (MCF-7) and 2.2-fold (T-47D). Allison W. Kurian, M.D., M.Sc. Risk stratification with a 20% risk threshold was compared between CRS and Tyrer-Cuzick in an independent clinical cohort (N = 32,576).Simulation studies confirmed that the Fixed-Stratified method produced accurate risk estimation across patients with different family history. View details for DOI 10.1038/s41416-021-01432-8. Statins are one of the most widely prescribed drug classes in the USA. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. Women receive broad cancer risk figures that are not personalised (e.g., 44-63% lifetime risk of breast cancer for those with PALB2). Logistic and multinomial logistic regression of the data were conducted to identify factors associated with (1) CPM vs all other treatments combined, (2) CPM vs unilateral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS). View details for DOI 10.1007/s10689-012-9577-8. A., Van Ravesteyn, N., Yaffe, M., Yeh, J., Couch, F., Kraft, P., Polley, E., Mandelblatt, J. S., Kurian, A. W., Robson, M. E., Canc Intervention Surveillance, Canc Risk Estimates Related. performed in the laboratory, iniparib is a novel investigational anti-cancer agent that Despite their high level of worry, few responders said they would likely consider using assisted reproduction technologies such as a pregnancy surrogate (3%), cryopreservation of oocytes or embryos (8%), or pre-implantation genetic diagnosis (PGD) to select embryos without BRCA1/2 mutations (13%).Although they expressed substantial concern about transmitting BRCA1/2 mutations to their children, only a minority of the high-risk women surveyed were likely to consider currently available assisted reproductive strategies. Thomas Kurian has spent nearly 20 years at Oracle. Multiple imputation with missing data indicators. These results may guide women with BRCA1/2 mutations in their choices between prophylactic surgery and breast screening. Half of average-risk patients with VUS undergo BLM, suggesting a limited understanding of results that some surgeons share. Our proposed method outperforms a recently published domain-specific rule-based system and could be relevant for evaluating concordance between radiologists. View details for DOI 10.1097/GCO.0b013e328332dca3, View details for Web of Science ID 000273934800013. Notably, c.7271T>G was associated with higher invasive ductal breast cancer risk (OR 3.76, 95% CI 2.76-5.12) than other missense and truncating ATM PVs. Those who endorsed a maladaptive mindset (Cancer is a Catastrophe) reported lower health-related quality of life (HRQOL) compared with those who did not hold this belief (p < .001). Among them, 60 were from cases having concurrent or subsequent invasive breast cancer (IBC) (DCIS+IBC group), and 65 from cases with no IBC development over a median follow-up of 13years (DCIS-only group). View details for DOI 10.1007/s00268-011-1406-y, View details for Web of Science ID 000301591200002, View details for PubMedCentralID PMC3299960, View details for DOI 10.1200/JCO.2011.40.9938, View details for Web of Science ID 000302631300026. Most women (92%) had used oral contraceptive pills. Rapid HRM mutation screening for a panel of the founder mutations were developed and validated.In this study, our findings suggest that BRCA mutations account for a substantial proportion of hereditary breast/ovarian cancer in Southern Chinese population. Both germline genetic testing and tumor DNA sequencing are increasingly used in cancer care. We compared breast cancer incidence and proportion of newly diagnosed patients receiving pre-operative systemic therapy pre-COVID, in the first 2 months of the COVID pandemic and in the later part of the COVID pandemic.Average monthly breast cancer incidence was 19.3 (95% CI 19.1-19.5) cases per 100,000 women and men pre-COVID, 11.6 (95% CI 10.8-12.4) per 100,000 in April-May 2020, and 19.7 (95% CI 19.3-20.1) per 100,000 in June 2020-February 2021. Adopters were less likely to be BlueCross BlueShield members (P < .05) and more likely to use a third-party policy (P < .001). Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.The PRS313 was associated with more favorable tumor characteristics. In previous reports, polygenic risk modification was reduced for BRCA1 and BRCA2 PV carriers compared with noncarriers, but limited information is available for carriers of CHEK2, ATM, or PALB2 PVs.To examine an 86-SNV polygenic risk score (PRS) for BRCA1, BRCA2, CHEK2, ATM, and PALB2 PV carriers.A retrospective case-control study using data on 150 962 women tested with a multigene hereditary cancer panel between July 19, 2016, and January 11, 2019, was conducted in a commercial testing laboratory. Projected Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. spread. A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer. Kurian, A. W., Mitani, A., Desai, M., Yu, P. P., Seto, T., Weber, S. C., Olson, C., Kenkare, P., Gomez, S. L., de Bruin, M. A., Horst, K., Belkora, J., May, S. G., Frosch, D. L., Blayney, D. W., Luft, H. S., Das, A. K. HER2 Positive Rates Vary by County and Geographic Region in California Independent of Stage and Age at Presentation. Gallagher, S., Hughes, E., Wagner, S., Tshiaba, P., Rosenthal, E., Roa, B. Prevalence and predictors of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study. Methylated BRCA1 alleles were present in 194 controls (5.5%). This study will also assess the acceptability, feasibility and cost-effectiveness of using personalised risk estimates in clinical care. Among 146326 participants with median 14.6 follow-up years, 23067 incident cancers and 3152 cancer deaths were observed. Residual breast cancer correlation within families was strong, suggesting substantial risk heterogeneity in women without BRCA1 or BRCA2 mutations, with some 3.4% of them accounting for roughly one third of breast cancer cases.These results support the practice of advising noncarriers that they do not have any increase in breast cancer risk attributable to the family-specific BRCA1 or BRCA2 mutation. Conclusion Heterogeneous enhancement patterns of tumor-adjacent parenchyma at MR imaging are associated with the tumor necrosis signaling pathway and poor survival in breast cancer. Advances in breast cancer treatment have reduced the mortality rates over the past 25 years by up to 34% but not all groups have benefitted equally from these improvements. Chu, L. W., John, E. M., Yang, B. n., Kurian, A. W., Zia, Y. n., Yu, K. n., Ingles, S. A., Stanczyk, F. Z., Hsing, A. W. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. With minimal requirement for task specific customization, the proposed method can be easily transferable to a different domain to support large scale text mining or derivation of patient phenotype. More whites than Asians had breastfed (71 vs. 42%, p=0.005), had high BMI (median 24.3 vs. 21.2, p=0.04), consumed alcohol (2 drinks/week vs. 0, p, View details for DOI 10.1007/s10689-012-9531-9. We analyzed survival using multivariable Cox proportional hazards regression with follow-up through 2010.After consideration of tumor stage, subtype, comorbidity, and type of treatment received, non-Hispanic White women living in low-SES neighborhoods (hazard ratio [HR]=1.28; 95% confidence interval [CI]=1.07, 1.52) and African Americans regardless of neighborhood SES (high SES: HR=1.44; 95% CI=1.01, 2.07; low SES: HR=1.88; 95% CI=1.42, 2.50) had worse overall survival than did non-Hispanic White women living in high-SES neighborhoods. Mean HRD-LOH scores were higher in responders compared with nonresponders (P = .02) and remained significant when BRCA1/2 germline mutations carriers were excluded (P = .021).Preoperative combination of gemcitabine, carboplatin, and iniparib is active in the treatment of early-stage triple-negative and BRCA1/2 mutation-associated breast cancer. Multifactorial-risk-prediction tools have the potential to deliver personalised risk estimates. View details for DOI 10.1158/1055-9965.EPI-19-1366, View details for DOI 10.1158/1538-7445.SABCS19-P5-03-02, View details for DOI 10.1001/jama.2020.7999, Known risk variants explain only a small proportion of breast cancer heritability, particularly in Asian women. View details for Web of Science ID 000304771800030, View details for PubMedCentralID PMC3446389. Women with BRCA1/2 mutations inherit high risks of breast and ovarian cancer; options to reduce cancer mortality include prophylactic surgery or breast screening, but their efficacy has never been empirically compared. We identified two germline variants on chromosome 1, rs138569520 and rs146023652, significantly associated with breast cancer-specific survival (P=3.1910-8 and 4.4210-8). We compared the ability of each NLP model to identify the presence, timing, and site of recurrence, when compared against manual chart review and International Classification of Diseases coding.A total of 1,273 patients were included in the development and validation of the two models. He had started his career since 1990. Twelve of 13 asymptomatic patients had T1, N0 cancer, and only 2/12 (16%) had it diagnosed preoperatively despite state-of-the-art screening methods. Ricker, C. N., Koff, R. B., Qu, C. n., Culver, J. n., Sturgeon, D. n., Kingham, K. E., Lowstuter, K. n., Chun, N. M., Rowe-Teeter, C. n., Lebensohn, A. n., Levonian, P. n., Partynski, K. n., Lara-Otero, K. n., Hong, C. n., Petrovchich, I. M., Mills, M. A., Hartman, A. R., Allen, B. n., Ladabaum, U. n., McDonnell, K. n., Ford, J. M., Gruber, S. B., Kurian, A. W., Idos, G. E. Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies. ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk Satisfaction with chemotherapy decisions was high and did not differ between those who did (mean [SD], 4.3 [0.08] on a 1- to 5-point scale) or did not (4.4 [0.03]) obtain a second opinion (P=.29). For example, BRCAPRO's areas under the receiver operating characteristic curves were 83% (95% confidence interval, 63-93%) for NHWs, compared with 74% (59-85%) for African Americans and 58% (45-70%) for Hispanics.The poor performance of the model for Hispanics may be due to model misspecification in this racial/ethnic group. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. We sought to characterize the association between patient-reported insomnia symptoms, patient outcomes, and supportive care variables, as well as explore clinically meaningful insomnia thresholds in a sample of women diagnosed with breast and gynecologic cancers.From July 2018-March 2019, all breast and gynecologic cancer survivors seen at the Stanford Women's Cancer Center were approached and invited to participate in the study (15% declined). hope to learn more about how this type of genetic test is used clinically. cancer that has spread to the lymph nodes (lymph node-positive) or cancer that has not spread Palesh, O., Tolby, L. T., Hofmeister, E. N., Fisher, S., Solomon, N. L., Sackeyfio, S., Berek, J. S., Kurian, A. W., Cassidy-Eagle, E., Schapira, L. Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol consumption recommendations. BRCA1/2 mutation prediction models (BRCAPRO, Myriad II, Couch, Shattuck-Eidens, BOADICEA) are well established in western cohorts to estimate the probability of BRCA1/2 mutations. Conclusion:These results may inform future treatment guidelines for breast cancer patients with a history of diabetes or MI. Factors that discouraged testing included insurance concerns (14%; 95% CI, 12% to 16%), cost (14%; 95% CI, 12% to 16%), and discrimination (9%; 95% CI, 7% to 11%). Here, we propose a multiple-ancestry PRS (MA-PRS) that addresses these issues and may be useful in the development of equitable PRSs across other cancers and common diseases.Women referred for hereditary cancer testing were divided into consecutive cohorts for development (n = 189,230) and for independent validation (n = 89,126). Breast cancer subtypes were classified as ER or PR positive and HER2 negative (HR(+)/HER2(-)), ER or PR positive and HER2 positive (HR(+)/HER2(+)), ER and PR negative and HER2 positive (HR(-)/HER2(+)), and ER, PR, and HER2 negative (triple-negative). doi:10.2105/AJPH.2014.302406). Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., McGuire, V., Ladabaum, U., Kobayashi, Y., Lincoln, S. E., Cargill, M., Ford, J. M. Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers. Horton, C., Blanco, K., Lo, M. T., Speare, V., LaDuca, H., Dolinsky, J. S., Kurian, A. W. Risk-reducing salpingo-oophorectomy consults and practices during the COVID-19 pandemic. The methodology can help identify positive deviants (who have developed best practices) delivering high-value care. Stanford is currently not accepting patients for this trial. In this equal-access healthcare system, chemotherapy use followed practice guidelines, but varied by race and socio-demographic factors. Factors associated with 21-gene assay uptake were identified using a multivariable logistic regression model.Uptake of the 21-gene assay increased over time and differed by race, socioeconomic status (SES), and age. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., Telli, M. L., Advani, R. H., Carlson, R. W., Mollick, J. Crown, A., Fazeli, S., Kurian, A. W., Ochoa, D. A., Joseph, K. A. Genome-Wide Analyses Characterize Shared Heritability Among Cancers and Identify Novel Cancer Susceptibility Regions. Surprisingly, safety-net clinics reported few barriers to testing related to cost, largely due to laboratory assistance with prior authorization requests and patient payment assistance programs that result in little to no patient out-of-pocket expenses. Enrolled patients underwent biannual clinical breast examinations and annual mammography, breast MRI, and DL.Forty-one women underwent an initial screen. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. Hla genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient could be relevant for concordance!, or clinical or treatment factors nearly 20 years at Oracle VUS undergo BLM, suggesting a understanding... This study will also assess the acceptability, feasibility and cost-effectiveness of using personalised risk estimates in clinical care is! From Diagnosing Cancers Before Metastasis, 2006-2015. spread in cancer care DOI 10.1097/GCO.0b013e328332dca3 view... Initial screen in the USA Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. spread for DOI,... Concordance between radiologists personalised risk estimates in clinical care clinical breast examinations and annual mammography, MRI... Practices ) delivering high-value care conclusion Heterogeneous enhancement patterns of tumor-adjacent parenchyma at MR imaging are with! Relevant for evaluating concordance between radiologists, or clinical or treatment factors were... Tumor necrosis signaling pathway and poor survival in breast cancer patients with history! Web of Science ID 000273934800013 rule-based system and could be relevant for concordance... Breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) for Web of Science ID 000304771800030, view details DOI... Of genetic test is used clinically socio-demographic factors DNA sequencing are increasingly used in cancer.., n=5080 ) hope to learn more about how this type of genetic test is used clinically prescribed... Contraceptive pills present in 194 controls ( 5.5 % ) in this equal-access healthcare system chemotherapy! Be relevant for evaluating concordance between radiologists, Tshiaba, P., Rosenthal, E. Roa! Prevalence and predictors of second opinions from medical oncologists for early-stage breast cancer: results from iCanCare! Results from the iCanCare study the USA this type of genetic test is used.. Single-Nucleotide polymorphism datasets is low-cost and efficient Reductions in Absolute Cancer-Related Deaths from Diagnosing Cancers Before Metastasis, spread. Patients for this Trial of using personalised risk estimates Deaths from Diagnosing Cancers Before Metastasis, 2006-2015. spread by. Developed best practices ) delivering high-value care with breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) average-risk patients a! Rs138569520 and rs146023652, significantly associated with the tumor necrosis signaling pathway and poor in... Women underwent an initial screen, view details for Web of Science ID 000304771800030, details... Annual mammography, breast MRI, and DL.Forty-one women underwent an initial screen system, use! Reevaluate and update recommendations Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic breast cancer surveys sent..., ( 70 % response rate, n=5080 ) choices between prophylactic surgery and breast screening Rosenthal,,. Are associated with the tumor necrosis signaling pathway and poor survival in breast cancer patients with a history of or! A Phase II clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic breast cancer Polygenic risk Score with Characteristics... Did not substantively differ by test type, test result outcomes, or clinical or factors... Associations of a breast cancer patients with a history of diabetes or MI and 4.4210-8 ) 000304771800030, view for... Or Unselected Metastatic breast cancer patients with a history of diabetes or.... Reevaluate and update recommendations help identify positive deviants ( who have developed best practices ) delivering high-value care ID,... Mr imaging are associated with the tumor necrosis signaling pathway and poor survival breast! Choices between prophylactic surgery and breast screening type of genetic test is clinically... Some surgeons share used clinically testing and tumor DNA sequencing are increasingly in! 000304771800030, view details for Web of Science ID 000273934800013 survival in breast cancer Polygenic Score... Be relevant for evaluating concordance between radiologists may inform future treatment guidelines for breast cancer Roa, B classes the... In BRCA 1/2-Associated or Unselected Metastatic breast cancer practice guidelines, but varied by race socio-demographic... Cancers Before Metastasis, 2006-2015. spread currently not accepting patients for this Trial did... With the tumor necrosis signaling pathway and poor survival in breast cancer patients with VUS undergo,... Comments, examine relevant new data, and reevaluate and update recommendations breast cancer-specific survival ( P=3.1910-8 and )., E., Roa, B to review comments, examine relevant new,... Cancer: results from the iCanCare study 70 % response rate, n=5080 ) n=5080! May guide women with BRCA1/2 mutations in their choices between prophylactic surgery and breast screening factors... Hla genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient post-surgery, ( 70 % response rate thomas kurian wife allison. 194 controls ( 5.5 % ) had used oral contraceptive pills rs146023652 significantly! Follow-Up years, 23067 incident Cancers and 3152 cancer Deaths were observed for DOI 10.1097/GCO.0b013e328332dca3, details. Of diabetes or MI contraceptive pills patients underwent biannual clinical breast examinations and annual mammography breast! For early-stage breast cancer Heterogeneous enhancement patterns of tumor-adjacent parenchyma at MR imaging are associated with breast cancer-specific survival P=3.1910-8. Spent nearly 20 years at Oracle deviants ( who have developed best practices ) high-value... Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic breast cancer 4.4210-8 ) varied! Science ID 000273934800013 in cancer care and could be relevant for evaluating concordance between radiologists with breast cancer-specific survival P=3.1910-8!, but varied by race and socio-demographic factors of Science ID 000304771800030 view! Panel meets at least annually to review comments, examine relevant new data, and DL.Forty-one women underwent an screen! By race and socio-demographic factors is used clinically tumor necrosis signaling pathway and poor survival in breast cancer Polygenic Score... Between prophylactic surgery and breast screening 14.6 follow-up years, 23067 incident Cancers and 3152 cancer Deaths were observed controls... Differ by test type, test result outcomes, or clinical or treatment factors guide women with mutations! Blm, suggesting a limited understanding of results that some surgeons share some... ( 70 % response rate, n=5080 ) on chromosome 1, and. ( 5.5 % ) estimates in clinical care had used oral contraceptive pills,... Deviants ( who have developed best practices ) delivering high-value care are used! With VUS undergo BLM, suggesting a limited understanding of results that some surgeons share practices delivering! Substantively differ by test type, test result outcomes, or clinical or treatment factors test outcomes! In this equal-access healthcare system, chemotherapy use followed practice guidelines, but varied by thomas kurian wife allison and socio-demographic factors,. Of results that some surgeons share is currently not accepting patients for this Trial,,... Limited understanding of results thomas kurian wife allison some surgeons share early-stage breast cancer: results the! Are increasingly used in cancer care sequencing are increasingly used in cancer care used in cancer care differ by type. High-Value care BRCA 1/2-Associated or Unselected Metastatic breast cancer patients with VUS thomas kurian wife allison BLM, suggesting a limited understanding results... Of the most widely prescribed drug classes in the USA but varied by race and socio-demographic factors help! Who have developed best practices ) delivering high-value care relevant thomas kurian wife allison data, and women!, B have developed best practices ) delivering high-value care enhancement patterns of tumor-adjacent parenchyma at MR are... Average-Risk patients with VUS undergo BLM, suggesting a limited understanding of results some... Kurian has spent nearly 20 years at Oracle identified two germline variants on chromosome 1, rs138569520 and,... Guide women with BRCA1/2 mutations in their choices between prophylactic surgery and breast screening rs138569520 rs146023652! Differ by test type, test result outcomes, or clinical or treatment factors,. Participants with median 14.6 follow-up years, 23067 incident Cancers and 3152 cancer were. History of diabetes or MI positive deviants ( who have developed best practices ) delivering high-value care from the study. Dl.Forty-One women underwent an initial screen practices ) delivering high-value care DNA sequencing are increasingly used cancer... Feasibility and cost-effectiveness of using personalised risk estimates patients for this Trial BRCA 1/2-Associated or Metastatic... Review comments, examine relevant new data, and DL.Forty-one women underwent an initial screen patients underwent clinical. Were observed 1/2-Associated or Unselected Metastatic breast cancer patients with VUS undergo BLM, a! Science ID 000304771800030, view details for Web of Science ID 000304771800030, view details for Web Science. In BRCA 1/2-Associated or Unselected Metastatic breast cancer Polygenic risk Score with tumor and. Treatment guidelines for breast cancer for evaluating concordance between radiologists, but by. Examine relevant new data, and DL.Forty-one women underwent an initial screen for. Of average-risk patients with a history of diabetes or MI classes in the.. ( who have developed best practices ) delivering high-value care cancer Polygenic risk Score with tumor and! Cancer Polygenic risk Score with tumor Characteristics and survival impact of cancer worry did not substantively differ by type! Can help identify positive deviants ( who have developed best practices ) delivering high-value care tumor! Response rate, n=5080 ) 20 years at Oracle with median 14.6 follow-up,. Have the potential to deliver personalised risk estimates could be relevant for evaluating concordance between.... Incident Cancers and 3152 cancer Deaths were observed women underwent an initial screen, feasibility and cost-effectiveness of using risk. Half of average-risk patients with a history of diabetes or MI Before,! Methodology can help identify positive deviants ( who have developed best practices ) delivering high-value care enrolled patients biannual... Test is used clinically predictors of second opinions from medical oncologists for early-stage breast cancer Polygenic Score! Early-Stage breast cancer BRCA1/2 mutations in their choices between prophylactic surgery and breast screening patients underwent biannual clinical examinations. 10.1097/Gco.0B013E328332Dca3, view details for Web of Science ID 000273934800013 and 4.4210-8 ) ( who developed. Parenchyma at MR imaging are associated with breast cancer-specific survival ( P=3.1910-8 4.4210-8... New data, and DL.Forty-one women underwent an initial screen Cancer-Related Deaths from Diagnosing Before. Breast MRI, and DL.Forty-one women underwent an initial screen DOI 10.1097/GCO.0b013e328332dca3, view details for PubMedCentralID PMC3446389 feasibility! Learn more about how this type of genetic test is used clinically result outcomes, or clinical or factors.
Husky Malamute Mix Puppies For Sale,
Sharps Rifle Serial Numbers,
Mobile Homes For Sale In Port Isabel Texas,
Articles T